[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 28 of about 28
1. Hassan R, Bullock S, Premkumar A, Kreitman RJ, Kindler H, Willingham MC, Pastan I: Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers. Clin Cancer Res; 2007 Sep 1;13(17):5144-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers.
  • EXPERIMENTAL DESIGN: SS1P given as a 30-min i.v. infusion every other day (QOD) for six or three doses was administered to 34 patients with advanced mesothelioma (n = 20), ovarian (n = 12), and pancreatic (n = 2) cancer.
  • Phase II clinical trials of SS1P are being planned for malignant mesothelioma and other mesothelin-expressing malignancies.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Immunotoxins / administration & dosage. Mesothelioma / drug therapy. Ovarian Neoplasms / drug therapy. Pancreatic Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17785569.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Immunotoxins; 0 / SS1(dsFv)PE38
  •  go-up   go-down


2. Davidson B, Skrede M, Silins I, Shih IeM, Trope CG, Flørenes VA: Low-molecular weight forms of cyclin E differentiate ovarian carcinoma from cells of mesothelial origin and are associated with poor survival in ovarian carcinoma. Cancer; 2007 Sep 15;110(6):1264-71
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low-molecular weight forms of cyclin E differentiate ovarian carcinoma from cells of mesothelial origin and are associated with poor survival in ovarian carcinoma.
  • BACKGROUND: The authors recently reported on the role of cyclin E in differentiating ovarian/primary peritoneal carcinoma from malignant peritoneal mesothelioma using gene expression arrays.
  • In the current study, they analyzed the expression of low-molecular weight (LMW) forms of cyclin E in ovarian carcinoma, malignant mesothelioma, and benign reactive effusions.
  • METHODS: Cyclin E protein expression was analyzed in 98 effusions (72 ovarian carcinomas, 14 malignant mesotheliomas, and 12 reactive specimens) using immunoblotting.
  • Sixty-two ovarian carcinoma effusions were studied further for cyclin E expression using immunohistochemistry.
  • The correlations between cyclin E expression in ovarian carcinoma and clinical parameters, including chemotherapy response, were analyzed.
  • RESULTS: LMW forms of cyclin E were identified in 54 of 72 ovarian carcinoma effusions (75%) compared with 1 of 14 malignant mesothelioma effusions (7%) and 1 of 12 reactive effusions (8%) (P < .001).
  • Their presence in ovarian carcinoma was associated with a higher percentage of cyclin E-positive cells (P = .001) and increased staining intensity (P < .001) using immunohistochemistry.
  • No association with chemotherapy response was observed.
  • CONCLUSIONS: LMW forms of cyclin E differentiated ovarian carcinoma from benign and malignant mesothelial cells and were associated with increased protein expression using immunohistochemistry.
  • The expression of LMW cyclin E forms was not associated with chemotherapy response, although it may be a marker of aggressive disease in patients with metastatic ovarian carcinoma.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma / chemistry. Carcinoma / mortality. Cyclin E / analysis. Mesothelioma / chemistry. Mesothelioma / mortality. Ovarian Neoplasms / chemistry. Ovarian Neoplasms / mortality

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 American Cancer Society.
  • (PMID = 17647260.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cyclin E
  •  go-up   go-down


3. Yan TD, Stuart OA, Yoo D, Sugarbaker PH: Perioperative intraperitoneal chemotherapy for peritoneal surface malignancy. J Transl Med; 2006;4:17
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Perioperative intraperitoneal chemotherapy for peritoneal surface malignancy.
  • The treatment of peritoneal surface malignancy mainly focuses on diffuse malignant peritoneal mesothelioma, pseudomyxoma peritonei from appendiceal cancer, and peritoneal dissemination from gastrointestinal and ovarian cancers.
  • Recently, cytoreductive surgery combined with perioperative intraperitoneal chemotherapy has shown an improved survival in selected patients with this disease.
  • To date, multiple different treatment regimens of perioperative intraperitoneal chemotherapy have been used.
  • This review focuses on the perioperative intraperitoneal chemotherapy currently in use in conjunction with cytoreductive surgery for the treatment of peritoneal surface malignancy at the Washington Cancer Institute.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int Surg. 1999 Jan-Mar;84(1):60-6 [10421021.001]
  • [Cites] Cancer. 2000 Jan 1;88(1):58-65 [10618606.001]
  • [Cites] J Clin Oncol. 2000 Jan;18(1):136-47 [10623704.001]
  • [Cites] Lancet. 2000 Mar 25;355(9209):1041-7 [10744089.001]
  • [Cites] J Clin Oncol. 2000 Aug;18(16):2938-47 [10944126.001]
  • [Cites] Dis Colon Rectum. 2000 Oct;43(10):1341-6; discussion 1347-8 [11052509.001]
  • [Cites] Br J Surg. 2000 Nov;87(11):1587-93 [11091251.001]
  • [Cites] Eur J Cancer. 2001 May;37(8):979-84 [11334722.001]
  • [Cites] Eur J Surg Oncol. 2001 Apr;27(3):239-43 [11373099.001]
  • [Cites] Eur J Surg Oncol. 2001 Apr;27(3):286-90 [11373107.001]
  • [Cites] Cancer. 2001 Jul 1;92(1):71-6 [11443611.001]
  • [Cites] World J Surg. 2001 Aug;25(8):985-90 [11571980.001]
  • [Cites] Am Surg. 2001 Oct;67(10):999-1003 [11603562.001]
  • [Cites] Am J Surg. 2002 May;183(5):529-32 [12034386.001]
  • [Cites] Eur J Surg Oncol. 2003 Apr;29(3):261-5 [12657237.001]
  • [Cites] Ann Surg Oncol. 2003 May;10(4):463-8 [12734097.001]
  • [Cites] J Clin Oncol. 2003 Sep 1;21(17):3194-200 [12860964.001]
  • [Cites] J Clin Oncol. 2003 Oct 15;21(20):3737-43 [14551293.001]
  • [Cites] Surg Oncol Clin N Am. 2003 Jul;12(3):605-21, xi [14567020.001]
  • [Cites] Surg Oncol Clin N Am. 2003 Jul;12(3):755-69, xiv [14567029.001]
  • [Cites] Surg Oncol Clin N Am. 2003 Jul;12(3):771-80 [14567030.001]
  • [Cites] Semin Surg Oncol. 2003;21(4):233-48 [14648781.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4560-7 [14673042.001]
  • [Cites] Int J Gynecol Cancer. 2004 Jan-Feb;14(1):35-41 [14764027.001]
  • [Cites] World J Gastroenterol. 2004 Sep 15;10(18):2727-30 [15309728.001]
  • [Cites] J Clin Oncol. 2004 Aug 15;22(16):3284-92 [15310771.001]
  • [Cites] N Engl J Med. 2006 Jan 5;354(1):77-9 [16394306.001]
  • [Cites] Eur J Surg Oncol. 2006 Aug;32(6):686-91 [16621431.001]
  • [Cites] Cancer Treat Res. 1991;55:277-284 [1681861.001]
  • [Cites] Cancer Res. 1992 Mar 1;52(5):1252-8 [1737387.001]
  • [Cites] Cancer Res. 1990 Sep 15;50(18):5790-4 [2118420.001]
  • [Cites] Cancer. 1989 Jan 15;63(2):364-7 [2910444.001]
  • [Cites] Pharmacology. 1978;17(6):330-40 [32560.001]
  • [Cites] Cancer Chemother Pharmacol. 1983;11(1):1-4 [6883622.001]
  • [Cites] N Engl J Med. 1996 Jan 4;334(1):1-6 [7494563.001]
  • [Cites] World J Surg. 1995 May-Jun;19(3):450-4; discussion 455 [7639005.001]
  • [Cites] Biochem Pharmacol. 1993 Oct 5;46(7):1229-37 [8216374.001]
  • [Cites] Cancer. 1993 Jan 15;71(2 Suppl):517-23 [8420671.001]
  • [Cites] Cancer Res. 1979 Jun;39(6 Pt 2):2264-8 [87263.001]
  • [Cites] Cancer Treat Res. 1996;81:7-14 [8834571.001]
  • [Cites] Anticancer Drugs. 1996 Jul;7(5):596-603 [8862729.001]
  • [Cites] Cancer Chemother Pharmacol. 1998;41(2):147-54 [9443628.001]
  • [Cites] Cancer. 1999 Jun 15;85(12):2532-40 [10375099.001]
  • [Cites] Int J Hyperthermia. 1999 Mar-Apr;15(2):79-107 [10323618.001]
  • [Cites] Lancet. 1998 Oct 31;352(9138):1407-12 [9807986.001]
  • [Cites] J Pharmacol Exp Ther. 1999 Aug;290(2):871-80 [10411604.001]
  • (PMID = 16606461.001).
  • [ISSN] 1479-5876
  • [Journal-full-title] Journal of translational medicine
  • [ISO-abbreviation] J Transl Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1481500
  •  go-up   go-down


Advertisement
4. Scripcariu V, Dajbog E, Lefter L, Ferariu D, Pricop A, Grigoraş M, Dragomir C: [Malignant peritoneal mesothelioma]. Chirurgia (Bucur); 2006 Nov-Dec;101(6):641-6
Hazardous Substances Data Bank. ASBESTOS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant peritoneal mesothelioma].
  • Mesothelioma is a neoplasm originating from the mesothelial surface lining cells of the serous human cavities.
  • It may involve the pleura, less frequently the peritoneum rarely, the pericardium, the tunica vaginalis testis and ovarian epithelium.
  • A causal relationship between asbestos exposure and pleural, peritoneal and pericardial malign mesothelioma was suggested, the risk of cancer being correlated to cumulate exposure.
  • Studies from National Cancer Institute, USA, show that the malignant mesothelioma is a rare and aggressive asbestos related malignancy.
  • The symptomatology is insidious and poses difficult problems in diagnosis and treatment.
  • This paper presents the case of a 59 year old patient with malignant peritoneal mesothelioma who worked almost 40 years as an electrician, exposed to asbestos fibers.
  • It was performed surgical ablation of the tumor, splenectomy with favorable postoperative evolution, the patient being now under chemotherapy treatment.
  • [MeSH-major] Asbestos / adverse effects. Mesothelioma / etiology. Occupational Diseases / etiology. Peritoneal Neoplasms / etiology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Humans. Male. Middle Aged. Splenectomy. Tomography, X-Ray Computed. Treatment Outcome


5. Mohamed F, Sugarbaker PH: Peritoneal mesothelioma. Curr Treat Options Oncol; 2002 Oct;3(5):375-86
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peritoneal mesothelioma.
  • Peritoneal mesothelioma is usually a rapidly fatal primary peritoneal surface malignancy with a median survival time of less than 1 year, mainly because of lack of effective treatment.
  • Treatment options with intravenous chemotherapy are far from satisfactory.
  • However, because malignant peritoneal mesothelioma usually remains confined to the peritoneal cavity for most of its natural history, regional chemotherapy is an attractive option.
  • From a theoretic perspective, the treatments are most likely to succeed in selected patients with small-volume residual disease after cytoreductive surgery.
  • Advantages of intraperitoneal chemotherapy include greatly enhanced drug concentrations in the peritoneal cavity and decreased systemic toxicity.
  • In designing an intraperitoneal treatment strategy for the management of peritoneal mesothelioma, the limited number of active cytotoxic drugs and the timing of drug delivery pose problems.
  • Prognosis as determined by clinical presentation, the completeness of cytoreduction, and gender (female patients survive longer than male patients) appears to be improved by the use of intraperitoneal chemotherapy.
  • Over the past decade, the management of these patients has evolved similarly to ovarian cancer treatment and now involves cytoreductive surgery, heated intraoperative intraperitoneal chemotherapy with cisplatin and doxorubicin, and early postoperative intraperitoneal paclitaxel.
  • These perioperative treatments are followed by adjuvant intraperitoneal paclitaxel and second-look cytoreduction.
  • This multimodality treatment approach with debulking surgery and intraperitoneal chemotherapy has resulted in a median survival of 50 to 60 months.
  • Peritoneal mesothelioma is an orphan disease that is treatable, with expectations for "potential" cure in a small number of patients diagnosed and treated early with definitive local/regional treatments.
  • [MeSH-major] Mesothelioma / drug therapy. Mesothelioma / surgery. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / surgery
  • [MeSH-minor] Combined Modality Therapy. Humans

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Ind Med. 1960 Oct;17:260-71 [13782506.001]
  • [Cites] Lancet. 2001 Feb 10;357(9254):444-5 [11273069.001]
  • [Cites] Br J Surg. 2000 Nov;87(11):1587-93 [11091251.001]
  • [Cites] Cancer. 1984 Sep 1;54(5):951-60 [6331632.001]
  • [Cites] Cancer. 1983 Dec 1;52(11):1981-5 [6627213.001]
  • [Cites] Chest. 1988 Jan;93(1):159-62 [3335148.001]
  • [Cites] Ann Surg Oncol. 1999 Dec;6(8):790-6 [10622509.001]
  • [Cites] Semin Oncol. 2002 Feb;29(1):51-61 [11836669.001]
  • [Cites] Arch Surg. 1990 Nov;125(11):1477-81 [2241560.001]
  • [Cites] J Surg Oncol. 1999 Jan;70(1):6-12 [9989414.001]
  • [Cites] Cancer. 1983 Nov 15;52(10):1788-91 [6684983.001]
  • [Cites] Clin Oncol (R Coll Radiol). 1991 Nov;3(6):315-7 [1720658.001]
  • [Cites] Pathologe. 1999 May;20(3):169-76 [10412176.001]
  • [Cites] Cancer Treat Res. 1996;81:193-211 [8834586.001]
  • [Cites] J Cancer Res Clin Oncol. 1992;118(7):547-50 [1624547.001]
  • [Cites] Cancer. 1988 May 15;61(10):2019-21 [3282640.001]
  • [Cites] Ann Surg Oncol. 1999 Sep;6(6):582-90 [10493628.001]
  • [Cites] J Clin Oncol. 1988 Jan;6(1):147-53 [3335886.001]
  • [Cites] Ann Oncol. 1994;5 Suppl 6:S55-8 [7865436.001]
  • [Cites] J Clin Oncol. 1992 Sep;10(9):1485-91 [1355523.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Aug 29;97(18):10214-9 [10954737.001]
  • [Cites] Cancer. 1992 Dec 15;70(12):2969-79 [1451080.001]
  • [Cites] Cancer. 2000 Sep 15;89(6):1279-84 [11002223.001]
  • [Cites] Histopathology. 1997 May;30(5):403-18 [9181361.001]
  • [Cites] Am J Epidemiol. 1997 Feb 1;145(3):211-8 [9012593.001]
  • [Cites] Thorax. 1997 Jun;52(6):507-12 [9227715.001]
  • (PMID = 12194803.001).
  • [ISSN] 1527-2729
  • [Journal-full-title] Current treatment options in oncology
  • [ISO-abbreviation] Curr Treat Options Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 28
  •  go-up   go-down


6. Gupta NP, Kumar R: Malignant gonadal mesothelioma. Curr Treat Options Oncol; 2002 Oct;3(5):363-7
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant gonadal mesothelioma.
  • Malignant mesothelioma of the gonads is a rare and highly lethal disease.
  • However, intratesticular and ovarian mesotheliomas have also been described.
  • Occasionally, patients with localized disease at the time of detection have been known to survive for more than 10 years; however, the majority will not live beyond 5 years, with median survival being approximately 23 months.
  • The principle reasons for this are difficulty in making a preoperative diagnosis and advanced stage at the time of treatment.
  • Adjuvant therapy in the form of chemotherapy, immunotherapy, or radiotherapy has negligible benefit.
  • For advanced or recurrent disease, we suggest local radical resection with chemotherapy, including high-dose cisplatin and doxorubicin for two cycles of 5 days each; add local radiotherapy for uncontrolled locally advanced disease.
  • [MeSH-major] Genital Neoplasms, Male / drug therapy. Genital Neoplasms, Male / surgery. Mesothelioma / drug therapy. Mesothelioma / surgery

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Urol. 1990 Dec;144(6):1475-8 [2146405.001]
  • [Cites] Minerva Urol Nefrol. 2000 Mar;52(1):33-5 [11517828.001]
  • [Cites] Surg Today. 1999;29(10):1106-10 [10554340.001]
  • [Cites] Semin Diagn Pathol. 2000 Nov;17(4):294-306 [11202546.001]
  • [Cites] Br J Radiol. 1999 May;72(857):502-4 [10505018.001]
  • [Cites] Zentralbl Chir. 2001 Mar;126(3):229-32 [11301890.001]
  • [Cites] Cancer. 1998 Dec 15;83(12):2437-46 [9874447.001]
  • [Cites] Br J Urol. 1995 May;75(5):679-80 [7613813.001]
  • [Cites] Histopathology. 2000 Aug;37(2):150-9 [10931239.001]
  • [Cites] Jpn J Clin Oncol. 1991 Oct;21(5):377-83 [1753419.001]
  • [Cites] J Surg Oncol. 1999 Apr;70(4):251-4 [10219022.001]
  • [Cites] Ann Intern Med. 1984 Jan;100(1):19-24 [6197916.001]
  • [Cites] Am J Surg Pathol. 1995 Jul;19(7):815-25 [7793480.001]
  • [Cites] Urol Int. 1995;55(4):215-7 [8588269.001]
  • (PMID = 12194801.001).
  • [ISSN] 1527-2729
  • [Journal-full-title] Current treatment options in oncology
  • [ISO-abbreviation] Curr Treat Options Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 15
  •  go-up   go-down


7. Delage B, Fennell DA, Nicholson L, McNeish I, Lemoine NR, Crook T, Szlosarek PW: Arginine deprivation and argininosuccinate synthetase expression in the treatment of cancer. Int J Cancer; 2010 Jun 15;126(12):2762-72
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Arginine deprivation and argininosuccinate synthetase expression in the treatment of cancer.
  • Several tumours are arginine auxotrophic, due to variable loss of ASS1, including hepatocellular carcinoma, malignant melanoma, malignant pleural mesothelioma, prostate and renal cancer.
  • Several phase I/II clinical trials of the arginine-lowering drug, pegylated arginine deiminase, have shown encouraging evidence of clinical benefit and low toxicity in patients with ASS1-negative tumours.
  • In relapsed ovarian cancer, this is associated with platinum refractoriness.
  • In contrast, several platinum sensitive tumours, including primary ovarian, stomach and colorectal cancer, are characterised by ASS1 overexpression, which is regulated by proinflammatory cytokines.
  • This review examines the prospects for novel approaches in the prevention, diagnosis and treatment of malignant disease based on ASS1 pathophysiology and its rate-limiting product, arginine.
  • [MeSH-major] Arginine / metabolism. Argininosuccinate Synthase / metabolism. Neoplasms / enzymology. Neoplasms / therapy

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. (L)-ARGININE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20104527.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / / 12008; United Kingdom / Medical Research Council / / G0601891; United Kingdom / Cancer Research UK / / C12522/A8632
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 94ZLA3W45F / Arginine; EC 6.3.4.5 / Argininosuccinate Synthase
  • [Number-of-references] 86
  •  go-up   go-down


8. Hassan R, Ho M: Mesothelin targeted cancer immunotherapy. Eur J Cancer; 2008 Jan;44(1):46-53
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It is, however, highly expressed in several human cancers including malignant mesothelioma, pancreatic, ovarian and lung adenocarcinoma.
  • The normal biologic function of mesothelin is unknown but recent studies have shown that it binds to CA-125 and may play a role in the peritoneal spread of ovarian cancer.
  • The limited mesothelin expression in normal tissues and high expression in many cancers makes it an attractive candidate for cancer therapy.
  • These ongoing clinical trials will help define the utility of mesothelin as a target for cancer therapy.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Cancer Vaccines. Immunotherapy / methods. Membrane Glycoproteins / drug effects. Neoplasms / drug therapy
  • [MeSH-minor] Antibodies, Monoclonal / immunology. Antibodies, Monoclonal / therapeutic use. GPI-Linked Proteins. Genetic Vectors / therapeutic use. Humans. Listeria monocytogenes

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Rev Cancer. 2006 Jul;6(7):559-65 [16794638.001]
  • [Cites] Gynecol Oncol. 2007 Jun;105(3):563-70 [17400285.001]
  • [Cites] Cancer Res. 2003 Aug 1;63(15):4547-51 [12907630.001]
  • [Cites] Am J Surg Pathol. 2003 Nov;27(11):1418-28 [14576474.001]
  • [Cites] BMC Dev Biol. 2003 Apr 7;3:2 [12697065.001]
  • [Cites] Lancet. 2003 Nov 15;362(9396):1612-6 [14630441.001]
  • [Cites] J Biol Chem. 2004 Mar 5;279(10):9190-8 [14676194.001]
  • [Cites] Hum Pathol. 2004 Mar;35(3):357-66 [15017593.001]
  • [Cites] Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):3937-42 [15217923.001]
  • [Cites] Anticancer Res. 2004 May-Jun;24(3a):1327-35 [15274292.001]
  • [Cites] J Exp Med. 2004 Aug 2;200(3):297-306 [15289501.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Sep 21;101(38):13832-7 [15365184.001]
  • [Cites] N Engl J Med. 1983 Oct 13;309(15):883-7 [6310399.001]
  • [Cites] Int J Cancer. 1992 Feb 1;50(3):373-81 [1735605.001]
  • [Cites] Am J Surg Pathol. 1992 Mar;16(3):259-68 [1599018.001]
  • [Cites] Int J Cancer. 1992 Jun 19;51(4):548-54 [1351045.001]
  • [Cites] J Biol Chem. 1994 Jan 14;269(2):805-8 [8288629.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jan 9;93(1):136-40 [8552591.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jan 20;95(2):669-74 [9435250.001]
  • [Cites] Nat Biotechnol. 1999 Jun;17(6):568-72 [10385321.001]
  • [Cites] Gene Ther. 2005 Jan;12(2):187-93 [15526007.001]
  • [Cites] Clin Cancer Res. 2005 May 15;11(10):3814-20 [15897581.001]
  • [Cites] J Nucl Med. 2005 Jul;46(7):1201-9 [16000290.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2005 Sep;13(3):243-7 [16082249.001]
  • [Cites] Clin Cancer Res. 2005 Sep 1;11(17):6342-51 [16144939.001]
  • [Cites] Am J Clin Pathol. 2005 Dec;124(6):838-45 [16416732.001]
  • [Cites] Clin Cancer Res. 2006 Jan 15;12(2):447-53 [16428485.001]
  • [Cites] Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):827-31 [16467095.001]
  • [Cites] Clin Cancer Res. 2006 Aug 1;12(15):4695-701 [16899620.001]
  • [Cites] Clin Cancer Res. 2006 Aug 15;12(16):4983-8 [16914588.001]
  • [Cites] Mol Cancer. 2006;5(1):50 [17067392.001]
  • [Cites] Hum Pathol. 2007 Jan;38(1):1-16 [17056092.001]
  • [Cites] Clin Cancer Res. 2007 Mar 1;13(5):1571-5 [17332303.001]
  • [Cites] Oncogene. 1999 Dec 20;18(55):7860-72 [10630639.001]
  • [Cites] Mol Cell Biol. 2000 Apr;20(8):2902-6 [10733593.001]
  • [Cites] J Clin Oncol. 2001 Jan 1;19(1):145-56 [11134207.001]
  • [Cites] J Biol Chem. 2001 Jul 20;276(29):27371-5 [11369781.001]
  • [Cites] Clin Cancer Res. 2001 Dec;7(12):3862-8 [11751476.001]
  • [Cites] Clin Cancer Res. 2002 Nov;8(11):3520-6 [12429643.001]
  • [Cites] Am J Surg Pathol. 2003 Feb;27(2):150-8 [12548160.001]
  • [Cites] Mod Pathol. 2003 Mar;16(3):192-7 [12640097.001]
  • [Cites] Clin Cancer Res. 2007 Sep 1;13(17):5144-9 [17785569.001]
  • [Cites] Hum Pathol. 2003 Jun;34(6):605-9 [12827615.001]
  • (PMID = 17945478.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z01 BC010510-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antineoplastic Agents; 0 / Cancer Vaccines; 0 / GPI-Linked Proteins; 0 / MORAb-009 monoclonal antibody; 0 / Membrane Glycoproteins; 0 / SS1(dsFv)PE38; 0 / mesothelin
  • [Number-of-references] 46
  • [Other-IDs] NLM/ NIHMS38546; NLM/ PMC2265108
  •  go-up   go-down


9. Harrison LH Jr, Schwarzenberger PO, Byrne PS, Marrogi AJ, Kolls JK, McCarthy KE: Gene-modified PA1-STK cells home to tumor sites in patients with malignant pleural mesothelioma. Ann Thorac Surg; 2000 Aug;70(2):407-11
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene-modified PA1-STK cells home to tumor sites in patients with malignant pleural mesothelioma.
  • BACKGROUND: Malignant mesothelioma is an uncommon but lethal cancer of increasing incidence, particularly among patients with a history of exposure to asbestos.
  • Although numerous treatments have been employed, including chemotherapy, radiation therapy, surgical resection, and combinations of the above, no satisfactory treatment yet exists, and affected patients will die of this disease, usually within 12 months.
  • Gene-based therapies constitute a new approach that offers hope of improved control of these tumors while being associated with less morbidity than conventional chemotherapeutic or surgical regimens.
  • We demonstrated that PA1-STK cells home in vivo to mesothelioma deposits, a phenomenon that is required for optimal exertion of this therapeutic concept.
  • METHODS: Gene-modified ovarian cancer cells expressing the thymidine-kinase gene (PA1-STK) were radiolabeled with 99Tc and infused into the pleural space of 4 patients with malignant pleural mesothelioma, then scanned to determine distribution of the cells.
  • RESULTS: PA1-STK cells recognized and adhered preferentially to mesothelioma lining the chest wall.
  • CONCLUSIONS: Cell-based "suicide gene" therapy utilizing the "bystander effect" with the gene-modified ovarian cancer cell line PA1-STK is feasible in human pleural mesothelioma.
  • We have shown that this trafficking and homing of the therapeutic cells to the intrapleural tumor sites, a requirement for success with this novel therapeutic concept, is also valid in humans.
  • [MeSH-major] Genetic Therapy. Mesothelioma / therapy. Pleural Neoplasms / therapy. Simplexvirus / genetics. Thymidine Kinase / genetics
  • [MeSH-minor] Female. Humans. Ovarian Neoplasms / genetics. Radiopharmaceuticals. Technetium Compounds. Tomography, Emission-Computed, Single-Photon. Transduction, Genetic. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10969653.001).
  • [ISSN] 0003-4975
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0 / Technetium Compounds; EC 2.7.1.21 / Thymidine Kinase
  •  go-up   go-down


10. Kuku I, Kaya E, Sevinc A, Aydogdu I: Gemcitabine-induced erysipeloid skin lesions in a patient with malignant mesothelioma. J Eur Acad Dermatol Venereol; 2002 May;16(3):271-2
Genetic Alliance. consumer health - Mesothelioma, malignant.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gemcitabine-induced erysipeloid skin lesions in a patient with malignant mesothelioma.
  • Gemcitabine is a nucleoside analogue that has shown to have antineoplastic activity in different solid tumours (lung, pancreas, bladder, colon, ovarian, and breast cancer) and malignant mesothelioma.
  • We reported a male patient who developed erysipeloid skin reaction following gemcitabine treatment in the absence of radiotherapy and lymphedema.
  • [MeSH-major] Antimetabolites, Antineoplastic / adverse effects. Deoxycytidine / adverse effects. Deoxycytidine / analogs & derivatives. Drug Eruptions / etiology. Erysipeloid / chemically induced
  • [MeSH-minor] Humans. Liver Neoplasms / drug therapy. Male. Mesothelioma / drug therapy. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12195570.001).
  • [ISSN] 0926-9959
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


11. Garofalo A, Valle M, Garcia J, Sugarbaker PH: Laparoscopic intraperitoneal hyperthermic chemotherapy for palliation of debilitating malignant ascites. Eur J Surg Oncol; 2006 Aug;32(6):682-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic intraperitoneal hyperthermic chemotherapy for palliation of debilitating malignant ascites.
  • AIM: To report the use of laparoscopic Intraperitoneal Hyperthermic Chemotherapy (LIPHC) in the treatment of malignant ascites.
  • Ascites was from gastric cancer (5 cases), colorectal cancer (3 cases), ovarian cancer (3 cases), breast cancer (2 cases) and peritoneal mesothelioma (1 case).
  • Chemotherapy was cisplatin and doxorubicin or mitomycin depending on the type of primary tumor.
  • CONCLUSIONS: This method resulted in benefit for those peritoneal carcinomatosis patients with debilitating malignant ascites who were excluded from cytoreductive surgery.
  • Proficiency in laparoscopic staging procedures and experience in the management of carcinomatosis and intraperitoneal hyperthermic chemotherapy (IPHC) are required for the success of the procedure.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Ascites / drug therapy. Hyperthermia, Induced. Laparoscopy. Neoplasms / pathology. Palliative Care
  • [MeSH-minor] Aged. Cisplatin / administration & dosage. Doxorubicin / administration & dosage. Female. Humans. Infusions, Parenteral. Male. Middle Aged. Mitomycin / administration & dosage. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Palliative Care.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16631341.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


12. Koutselini HA, Lazaris AC, Thomopoulou G, Papayannopoulou A, Kairi-Vasilatou E: Papillary serous carcinoma of peritoneum: case study and review of the literature on the differential diagnosis of malignant peritoneal tumors. Adv Clin Path; 2001 Jul;5(3):99-104
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Papillary serous carcinoma of peritoneum: case study and review of the literature on the differential diagnosis of malignant peritoneal tumors.
  • The distinction between malignant mesothelioma and other malignant neoplasms diffusely involving the peritoneum is important for proper patient treatment.
  • The extra-ovarian peritoneal serous papillary carcinoma is a rare, primary, multicentric peritoneal tumor that is morphologically identical to ovarian serous carcinoma of equivalent grade, but can spare or minimally involve the ovaries.
  • We report such a tumor in a 65-year-old female who had abdominal swelling, ascites with positive cytology and a high grade of nuclear atypia in malignant cells as well as elevated serum CA125.
  • Since the amount of residual disease may be an important prognostic determining factor in primary papillary serous carcinoma of the peritoneum, the patient was debulked to no macroscopic disease and was then given platin-based chemotherapy.
  • The tumor's differential diagnosis from malignant mesothelioma was based, apart from morphologic criteria, on the tumor's immunoreactivity to MOC-31, Ber-EP4 and TAG-72, as well as on the lack of immunostaining for keratin 5/6 and calretinin.
  • Differential diagnosis from ovarian cancer was possible only after the pathological examination of the surgically resected ovaries; the tumor showed minimal superficial invasion of the ovarian cortex.
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / analysis. Cell Nucleus / pathology. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Diagnosis, Differential. Female. Humans. Mesothelioma / pathology. Ovarian Neoplasms / pathology. Paclitaxel / administration & dosage

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11753882.001).
  • [ISSN] 1125-5552
  • [Journal-full-title] Advances in clinical pathology : the official journal of Adriatic Society of Pathology
  • [ISO-abbreviation] Adv Clin Path
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


13. Muñoz-Casares FC, Rufián S, Rubio MJ, Lizárraga E, Díaz-Iglesias C, Aranda E, Ciria R, Muntané J, Barrios P, Torres-Melero J, González-Moreno S, González-Bayón L, Camps B, Bretcha P, Farré J, Ortega-Pérez G, Gómez-Portilla A: Treatment of peritoneal carcinomatosis from ovarian cancer. Present, future directions and proposals. Clin Transl Oncol; 2007 Oct;9(10):652-62
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of peritoneal carcinomatosis from ovarian cancer. Present, future directions and proposals.
  • Peritoneal carcinomatosis, considered years ago as a final stage of unresectable cancer, can now be managed with curative intention by means of a radical cytoreductive surgical procedure with associated peritonectomy and intraperitoneal chemotherapy, as described by Sugarbaker.
  • Malignant neoplasms such as mesothelioma and pseudomyxoma peritonei, ovarian and colon cancer nowadays are experiencing some new therapeutical approaches.
  • Higher survival rates can be reached in ovarian cancer, which is commonly diagnosed in the presence of peritoneal carcinomatosis, using an optimal cytoreductive radical surgery with intraperitoneal chemotherapy.
  • An actualised review of the treatment of advanced ovarian cancer and a proposal of a national multicentre protocol for the treatment of peritoneal carcinomatosis from ovarian cancer has been performed by a group of Spanish surgeons and oncologists dedicated to a therapeutical approach to this pathology.
  • [MeSH-major] Carcinoma / therapy. Ovarian Neoplasms / therapy. Peritoneal Neoplasms / therapy
  • [MeSH-minor] Combined Modality Therapy. Female. Humans. Patient Selection. Survival Analysis

  • Genetic Alliance. consumer health - Ovarian cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiol Clin North Am. 2002 May;40(3):609-36 [12117196.001]
  • [Cites] Eur J Surg Oncol. 2002 Feb;28(1):80-7 [11869020.001]
  • [Cites] Anticancer Res. 2003 May-Jun;23(3C):3019-27 [12926156.001]
  • [Cites] AJR Am J Roentgenol. 2002 Aug;179(2):391-5 [12130439.001]
  • [Cites] J Surg Oncol. 2000 May;74(1):41-4 [10861608.001]
  • [Cites] Hepatogastroenterology. 1994 Jun;41(3):207-13 [7959539.001]
  • [Cites] Eur J Surg Oncol. 2003 Feb;29(1):69-73 [12559080.001]
  • [Cites] J Surg Oncol. 2006 Sep 15;94(4):316-24 [16917864.001]
  • [Cites] Curr Oncol Rep. 2001 Jan;3(1):11-8 [11123864.001]
  • [Cites] Tumori. 2001 May-Jun;87(3):120-6 [11504363.001]
  • [Cites] Acta Chir Belg. 2004 Jun;104(3):246-56 [15285533.001]
  • [Cites] J Clin Oncol. 2006 Feb 1;24(4):571-8 [16446329.001]
  • [Cites] J Nippon Med Sch. 2000 Feb;67(1):5-8 [10777840.001]
  • [Cites] Gynecol Oncol. 2002 Mar;84(3):399-403 [11855877.001]
  • [Cites] Gynecol Oncol. 1991 Aug;42(2):146-50 [1894174.001]
  • [Cites] Gynecol Oncol. 2005 Feb;96(2):444-51 [15661234.001]
  • [Cites] Expert Opin Pharmacother. 2002 Jun;3(6):755-66 [12036415.001]
  • [Cites] Gynecol Oncol. 2003 Nov;91(2):341-5 [14599864.001]
  • [Cites] Curr Probl Surg. 1999 Jan;36(1):1-53 [9924485.001]
  • [Cites] N Engl J Med. 1996 Dec 26;335(26):1950-5 [8960474.001]
  • [Cites] Eur J Surg Oncol. 2006 Aug;32(6):671-5 [16621425.001]
  • [Cites] J Natl Cancer Inst. 2005 Apr 20;97(8):560-6 [15840878.001]
  • [Cites] Cancer Chemother Pharmacol. 1999;43(2):106-14 [9923815.001]
  • [Cites] Int J Gynecol Cancer. 2005 Nov-Dec;15 Suppl 3:241-6 [16343239.001]
  • [Cites] Cancer. 2001 Jun 15;91(12):2329-34 [11413522.001]
  • [Cites] Semin Oncol. 2006 Apr;33(2 Suppl 6):S3-11 [16716797.001]
  • [Cites] Int J Gynecol Cancer. 2005 Mar-Apr;15(2):233-9 [15823105.001]
  • [Cites] Ann Surg. 1995 Jan;221(1):29-42 [7826158.001]
  • [Cites] J Clin Oncol. 1995 Jul;13(7):1589-99 [7602348.001]
  • [Cites] Gynecol Oncol. 2004 Aug;94(2):325-32 [15297169.001]
  • [Cites] J Natl Cancer Inst. 2006 Nov 15;98(22):1655-63 [17105988.001]
  • [Cites] Ann Surg Oncol. 2004 May;11(5):518-21 [15123461.001]
  • [Cites] J Clin Oncol. 1996 Feb;14(2):351-6 [8636743.001]
  • [Cites] J Clin Oncol. 2003 Oct 15;21(20):3737-43 [14551293.001]
  • [Cites] Ann Surg Oncol. 2003 May;10 (4):463-8 [12734097.001]
  • [Cites] Eur J Surg Oncol. 2000 Nov;26(7):663-8 [11078613.001]
  • [Cites] N Engl J Med. 2006 Jan 5;354(1):34-43 [16394300.001]
  • [Cites] Bull Cancer. 2006 Jul;93(7):669-76 [16873075.001]
  • [Cites] J Cancer Res Clin Oncol. 2005 Jan;131(1):26-30 [15449183.001]
  • [Cites] J Clin Oncol. 1995 Dec;13(12):2961-7 [8523061.001]
  • [Cites] Oncologist. 2002;7 Suppl 5:20-8 [12324630.001]
  • [Cites] Lancet. 2002 Aug 17;360(9332):505-15 [12241653.001]
  • [Cites] N Engl J Med. 2004 Dec 9;351(24):2489-97 [15590951.001]
  • [Cites] Anticancer Res. 2002 Mar-Apr;22(2B):1329-36 [12168946.001]
  • [Cites] Radiology. 2002 May;223(2):495-9 [11997559.001]
  • [Cites] Cancer Treat Res. 1996;81:75-87 [8834577.001]
  • [Cites] Cancer Invest. 2001;19(6):597-602 [11486702.001]
  • [Cites] Int J Gynecol Cancer. 2001 Nov-Dec;11(6):466-70 [11906550.001]
  • [Cites] Radiology. 2000 Jun;215(3):761-7 [10831697.001]
  • [Cites] World J Surg. 2004 Oct;28(10):1040-5 [15573262.001]
  • [Cites] Int J Gynecol Cancer. 2003 Sep-Oct;13(5):587-92 [14675340.001]
  • [Cites] Gynecol Oncol. 2005 Oct;99(1):71-9 [16039699.001]
  • [Cites] Surg Oncol Clin N Am. 2003 Jul;12(3):825-33 [14567034.001]
  • [Cites] Int J Gynecol Cancer. 2003 Nov-Dec;13 Suppl 2:241-50 [14656286.001]
  • [Cites] Gynecol Oncol. 2007 Apr;105(1):90-6 [17173957.001]
  • [Cites] J Med Assoc Thai. 2001 Jul;84(7):958-65 [11759976.001]
  • [Cites] Gynecol Oncol. 2001 Nov;83(2):310-5 [11606090.001]
  • [Cites] G Chir. 1999 Mar;20(3):81-6 [10217864.001]
  • [Cites] Langenbecks Arch Chir Suppl Kongressbd. 1998;115:1435-7 [9931904.001]
  • [Cites] Expert Rev Anticancer Ther. 2001 Jun;1(1):142-8 [12113122.001]
  • [Cites] Semin Surg Oncol. 1999 Oct-Nov;17(3):181-8 [10504666.001]
  • [Cites] J Clin Oncol. 2003 Sep 1;21(17):3194-200 [12860964.001]
  • [Cites] J Surg Oncol. 2005 May 1;90(2):51-6; discussion 56-8 [15844187.001]
  • [Cites] Radiographics. 2004 Jan-Feb;24(1):209-23 [14730047.001]
  • [Cites] Int J Gynecol Cancer. 2003 Nov-Dec;13 Suppl 2:208-11 [14656282.001]
  • [Cites] Curr Oncol Rep. 1999 Sep;1(1):54-8 [11122798.001]
  • [Cites] Radiology. 1992 Jan;182(1):133-8 [1727276.001]
  • [Cites] J Clin Oncol. 2002 Mar 1;20(5):1248-59 [11870167.001]
  • [Cites] Am J Obstet Gynecol. 1994 Apr;170(4):974-9; discussion 979-80 [8166218.001]
  • [Cites] J Natl Cancer Inst. 2003 Sep 3;95(17):1320-9 [12953086.001]
  • [Cites] World J Surg Oncol. 2004 Jun 28;2:21 [15222884.001]
  • [Cites] Gynecol Oncol. 2004 Jan;92(1):147-51 [14751150.001]
  • [Cites] Eur J Gynaecol Oncol. 2002;23(5):405-10 [12440812.001]
  • [Cites] J Clin Oncol. 2001 Feb 15;19(4):1001-7 [11181662.001]
  • [Cites] Gynecol Oncol. 1995 Oct;59(1):25-33 [7557611.001]
  • [Cites] Semin Surg Oncol. 1998 Apr-May;14(3):254-61 [9548609.001]
  • [Cites] Tumori. 2004 Nov-Dec;90(6):556-61 [15762356.001]
  • [Cites] Eur J Surg Oncol. 2006 Aug;32(6):666-70 [16618534.001]
  • [Cites] Int J Gynecol Cancer. 2006 Jan-Feb;16 Suppl 1:74-8 [16515571.001]
  • [Cites] Gynecol Oncol. 1992 Nov;47(2):159-66 [1468693.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • (PMID = 17974526.001).
  • [ISSN] 1699-048X
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Review
  • [Publication-country] Italy
  • [Number-of-references] 83
  •  go-up   go-down


14. Dudek A, Larson T, Mellskog CE, Bloss LP, Obasaju C: A phase I clinical study of biweekly pemetrexed and gemcitabine in patients with advanced solid tumors. J Clin Oncol; 2004 Jul 15;22(14_suppl):2141

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The optimal sequence and schedule of both drugs is currently unknown.
  • Dose Escalation Levels with DLTs [Figure: see text] Results: Thus far, 24 patients (13 female, 11 male) with 1 or no prior chemotherapy; median age 61 (range 39 - 80); ECOG PS 0 (11), 1 (13); diagnoses: lung (10), malignant pleural mesothelioma (3), pancreas (3), breast (2), atypical carcinoid tumor (2), head and neck (1), ovarian (1), skin (1), unknown primary (1) have received a current total of 87 cycles (range 1-13/ patient).
  • Plans are to study this schedule in phase 2 trials in many tumor types where G and P are known to be active.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28016894.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Kolschmann S, Ballin A, Gillissen A: Clinical efficacy and safety of thoracoscopic talc pleurodesis in malignant pleural effusions. Chest; 2005 Sep;128(3):1431-5
Hazardous Substances Data Bank. TALC .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical efficacy and safety of thoracoscopic talc pleurodesis in malignant pleural effusions.
  • The purpose of this study was to determine the long-term efficacy and safety of pleurodesis by thoracoscopic talc poudrage (TTP) in malignant pleural effusions (MPEs).
  • One hundred eighty-day follow-up was completed for all patients, and outcome measures included time to recurrence of the effusion and survival.
  • Procedure-related complications were documented.
  • RESULTS: The most common primary neoplasms were lung cancer (n = 48), breast cancer (n = 16), and malignant pleural mesothelioma (n = 10).
  • Twenty-eight patients had other types of tumors, including renal cell carcinoma, ovarian carcinoma, GI tumors, prostate, malignant lymphoma, and unknown primary cancer.
  • Type of primary neoplasm had no significant influence on success rate.
  • Survival curves after 180 days showed significant differences, with best survival in mesothelioma and shortest life expectancy in lung cancer (p = 0.005).
  • Adverse effects included empyema in one case and malignant invasion of the scar.
  • [MeSH-major] Irritants / administration & dosage. Pleural Effusion, Malignant / drug therapy. Pleurodesis / methods. Talc / administration & dosage. Thoracoscopy / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16162739.001).
  • [ISSN] 0012-3692
  • [Journal-full-title] Chest
  • [ISO-abbreviation] Chest
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Irritants; 14807-96-6 / Talc
  •  go-up   go-down


16. Sioris T, Sihvo E, Salo J, Räsänen J, Knuuttila A: Long-term indwelling pleural catheter (PleurX) for malignant pleural effusion unsuitable for talc pleurodesis. Eur J Surg Oncol; 2009 May;35(5):546-51

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term indwelling pleural catheter (PleurX) for malignant pleural effusion unsuitable for talc pleurodesis.
  • AIMS: Talc pleurodesis using talc slurry via chest tube is a primary option in malignant pleural effusion, since life expectancy is short and surgical decortication is hazardous.
  • METHODS: Between March 2004 and September 2005, 51 consecutive patients with malignant pleural effusion, and clinically considered unsuitable for talc pleurodesis, received an indwelling pleural catheter (Denver PleurX).
  • There were 19 non-small cell lung cancer cases, 7 mesothelioma, and 25 with other malignancy.
  • Chemotherapy was being given to 18 patients and was not interrupted.
  • Mean survival was 3 months (range 5 days to 37+months) for all patients, with best median survivals of 5.5-6 months in breast and ovarian cancer.
  • CONCLUSIONS: An indwelling pleural catheter is a safe alternative for patients with malignant pleural effusion unsuitable for talc pleurodesis.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Catheters, Indwelling. Pleural Effusion, Malignant / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18644696.001).
  • [ISSN] 1532-2157
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


17. Boulikas T, Vougiouka M: Recent clinical trials using cisplatin, carboplatin and their combination chemotherapy drugs (review). Oncol Rep; 2004 Mar;11(3):559-95
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recent clinical trials using cisplatin, carboplatin and their combination chemotherapy drugs (review).
  • Cisplatin continues to play a central role in cancer chemotherapy in spite of its toxicity.
  • It is used as first-line chemotherapy against epithelial malignancies of lung, ovarian, bladder, testicular, head and neck, esophageal, gastric, colon and pancreatic but also as second- and third-line treatment against a number of metastatic malignancies including cancers of the breast, melanoma, prostate, mesothelioma, leiomyosarcomas, malignant gliomas and others.
  • Cisplatin has become the gold standard treatment against cervical cancer in combination with radiotherapy.
  • This review summarizes the state of the art on clinical trials published mainly in 2002 using cisplatin and carboplatin in their combinations with other anticancer drugs.
  • For most advanced cancers the response rate to chemotherapy is about 50% in first-line treatments and about 15% in second- or third-line treatments; for example response rates of 25-50% have been observed for chemonaive patients with advanced non-small cell lung cancer treated with cisplatin or carboplatin in combination with gemcitabine or taxanes and in exceptional cases these rates are up to 80% with addition of radiotherapy.
  • Response rates are very discouraging in second- or third-line chemotherapy treatments (7-25%).
  • Despite an increase in response rate from the use of modern-day chemotherapy drugs, no major difference in long-term survival has been achieved.
  • It is a high priority to invent novel approaches for cancer treatment.
  • It is hoped that a fraction of the numerous experimental drugs will show virtues in the anticancer arena especially combined with existing treatment regimens.
  • A preferential tumor targeting of chemotherapy treatments would bring a revolution in molecular medicine and would greatly advance cancer therapy in the upcoming years.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carboplatin / therapeutic use. Cisplatin / therapeutic use. Neoplasms / drug therapy
  • [MeSH-minor] Clinical Trials as Topic. Female. Humans. Male. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14767508.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Greece
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; Q20Q21Q62J / Cisplatin
  • [Number-of-references] 322
  •  go-up   go-down


18. Piso P, Slowik P, Popp F, Dahlke MH, Glockzin G, Schlitt HJ: Safety of gastric resections during cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis. Ann Surg Oncol; 2009 Aug;16(8):2188-94
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety of gastric resections during cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis.
  • BACKGROUND: Cytoreductive surgery (CRS) including gastric resection combined with hyperthermic intraperitoneal chemotherapy (HIPEC) can improve the prognosis of selected patients with peritoneal surface malignancies.
  • Perioperative morbidity of this aggressive treatment strategy is high; however, overall mortality can be low in specialized centers.
  • RESULTS: Of all patients included, 16 had pseudomyxoma peritonei, 11 gastric carcinoma, 4 ovarian carcinoma, 3 malignant peritoneal mesothelioma, and 3 colon carcinoma.
  • Twenty-seven patients had previous surgery (n = 22) and/or systemic chemotherapy (n = 18).
  • Fifteen total gastrectomies, 3 subtotal gastrectomies, 12 distal gastrectomies, and 7 gastric wedge resections were performed during CRS.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Gastrectomy. Hyperthermia, Induced. Neoplasms / drug therapy. Neoplasms / surgery. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Anastomosis, Surgical. Chemotherapy, Cancer, Regional Perfusion. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Staging. Postoperative Complications. Prognosis. Risk Factors. Safety. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19408049.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Yang XJ, Li Y, al-shammaa Hassan AH, Yang GL, Liu SY, Lu YL, Zhang JW, Yonemura Y: Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival in selected patients with peritoneal carcinomatosis from abdominal and pelvic malignancies: results of 21 cases. Ann Surg Oncol; 2009 Feb;16(2):345-51
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival in selected patients with peritoneal carcinomatosis from abdominal and pelvic malignancies: results of 21 cases.
  • We evaluated the perioperative safety profile and efficacy of cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) in 21 patients with peritoneal carcinomatosis (PC) from gastrointestinal and gynecological cancers.
  • Twenty-one patients with PC (12 gastric cancer, 5 colorectal cancer, 2 ovarian cancer, 1 pseudomyxoma peritonei, 1 malignant mesothelioma) were treated with CRS + HIPEC with hydroxycamptothecin 20 mg and mitomycin C 30 mg in 12,000 mL of normal saline at 43 +/- .5 degrees C for 60 to 90 minutes.
  • We analyzed the following: local and systemic infections; gastrointestinal function recovery; hematological, hepatic, and renal parameters; wound healing time; adverse events; survival; and quality of life.
  • Two patients developed generalized edema and were successfully treated.
  • Five patients developed hypoproteinemia on day 1 after surgery.
  • Time of gastric tube removal was 2 to 7 days.
  • Liquid food intake time was 3 to 8 days.
  • Time of removal of stitches was 8 to 18 days.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Cancer, Regional Perfusion. Hyperthermia, Induced. Peritoneal Neoplasms / mortality. Peritoneal Neoplasms / therapy
  • [MeSH-minor] Adenocarcinoma / mortality. Adenocarcinoma / secondary. Adenocarcinoma / therapy. Adult. Aged. Camptothecin / administration & dosage. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / secondary. Carcinoma, Squamous Cell / therapy. Colorectal Neoplasms / mortality. Colorectal Neoplasms / pathology. Colorectal Neoplasms / therapy. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Male. Mesothelioma / mortality. Mesothelioma / pathology. Mesothelioma / therapy. Middle Aged. Mitomycin / administration & dosage. Ovarian Neoplasms / mortality. Ovarian Neoplasms / pathology. Ovarian Neoplasms / therapy. Prognosis. Stomach Neoplasms / mortality. Stomach Neoplasms / pathology. Stomach Neoplasms / therapy. Survival Rate

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19018599.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


20. Verschraegen CF, Kumagai S, Davidson R, Feig B, Mansfield P, Lee SJ, Maclean DS, Hu W, Khokhar AR, Siddik ZH: Phase I clinical and pharmacological study of intraperitoneal cis-bis-neodecanoato( trans- R, R-1, 2-diaminocyclohexane)-platinum II entrapped in multilamellar liposome vesicles. J Cancer Res Clin Oncol; 2003 Oct;129(10):549-55
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I clinical and pharmacological study of intraperitoneal cis-bis-neodecanoato( trans- R, R-1, 2-diaminocyclohexane)-platinum II entrapped in multilamellar liposome vesicles.
  • Laparoscopy was performed on the first two courses for evaluation, adhesiolysis, and chemotherapy administration.
  • Afterwards, chemotherapy was administered through a peritoneal catheter.
  • Diagnoses were: malignant mesothelioma (six patients), signet ring cell (three), colon adenocarcinoma, pseudomyxoma peritonei, gastrointestinal stromal tumor (two each), and ovarian carcinoma (one).
  • Pharmacokinetics studies indicated a rapid but low absorption of drug into the systemic circulation, with a prolonged retention of platinum in the plasma compartment.
  • Peritoneal L-NDDP exposure was 17 to 49-times greater than in the plasma compartment.
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / metabolism. Adult. Aged. Area Under Curve. Ascites / metabolism. Carcinoma, Signet Ring Cell / drug therapy. Carcinoma, Signet Ring Cell / metabolism. Colorectal Neoplasms / drug therapy. Colorectal Neoplasms / metabolism. Endometrial Stromal Tumors / drug therapy. Endometrial Stromal Tumors / metabolism. Female. Humans. Injections, Intraperitoneal. Liposomes. Male. Mesothelioma / drug therapy. Mesothelioma / metabolism. Middle Aged. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / metabolism. Peritoneum / diagnostic imaging. Peritoneum / metabolism. Radionuclide Imaging. Technetium. Tissue Distribution

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TECHNETIUM, ELEMENTAL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1988 Aug 15;48(16):4509-12 [3396003.001]
  • [Cites] Ann Surg. 1995 Feb;221(2):124-32 [7857141.001]
  • [Cites] Cancer Chemother Pharmacol. 1991;28(4):315-7 [1879050.001]
  • [Cites] Cancer. 1997 Mar 1;79(5):884-91 [9041149.001]
  • [Cites] Semin Oncol. 1994 Apr;21(2 Suppl 2):17-9; quiz 20, 58 [8202717.001]
  • [Cites] Cancer Chemother Pharmacol. 1988;21(1):57-60 [3277734.001]
  • [Cites] Cancer Chemother Pharmacol. 2002 Jun;49(6):499-503 [12107555.001]
  • [Cites] Surg Oncol Clin N Am. 2001 Oct;10(4):915-33, xi [11641098.001]
  • [Cites] N Engl J Med. 1996 Dec 26;335(26):1950-5 [8960474.001]
  • [Cites] Hepatogastroenterology. 2001 Nov-Dec;48(42):1776-82 [11813623.001]
  • [Cites] J Med Chem. 1991 Jan;34(1):325-9 [1992134.001]
  • [Cites] Clin Cancer Res. 2002 Apr;8(4):1237-41 [11948138.001]
  • [Cites] Surg Clin North Am. 1978 Feb;58(1):131-42 [417410.001]
  • [Cites] Anal Biochem. 1987 May 15;163(1):21-6 [3039867.001]
  • [Cites] J Clin Oncol. 1995 Dec;13(12):2961-7 [8523061.001]
  • [Cites] Clin Cancer Res. 1997 Mar;3(3):373-9 [9815694.001]
  • [Cites] Surgery. 1993 Jun;113(6):631-6 [8506520.001]
  • [Cites] Cancer Chemother Pharmacol. 1989;24(1):1-8 [2720887.001]
  • [Cites] Semin Oncol. 1985 Sep;12(3 Suppl 4):23-8 [4048973.001]
  • [Cites] Dis Colon Rectum. 1993 Apr;36(4):323-9 [8458256.001]
  • [Cites] Cancer Res. 1990 Jul 15;50(14):4254-9 [2364384.001]
  • [Cites] J Clin Oncol. 2002 Oct 1;20(19):3944-6 [12351590.001]
  • [Cites] Cancer. 1996 Jun 15;77(12):2622-9 [8640714.001]
  • [Cites] Cancer. 1994 Apr 15;73(8):2048-52 [8156509.001]
  • [Cites] Cancer. 1988 Jan 15;61(2):232-7 [3121165.001]
  • [Cites] J Clin Oncol. 2001 Feb 15;19(4):1001-7 [11181662.001]
  • [Cites] J Microencapsul. 1994 Jan-Feb;11(1):41-54 [8138874.001]
  • [Cites] Cancer. 1990 Jan 1;65(1):65-71 [2104572.001]
  • (PMID = 14513369.001).
  • [ISSN] 0171-5216
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Liposomes; 0 / Organoplatinum Compounds; 113427-19-3 / bis-neodecanoato-1,2-diaminocyclohexaneplatinum(II); 7440-26-8 / Technetium
  •  go-up   go-down


21. Bagrova SG: [Results of phase II clinical trial of cycloplatam in refractory solid tumors]. Vopr Onkol; 2001;47(6):752-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Kurnakov Institute of General and Inorganic Chemistry in 1982, has been added to the arsenal of Russian cytostatic drugs.
  • Having passed phase I trials, it was approved for treatment of pleural mesothelioma, ovarian carcinoma and multiple myeloma.
  • They include treatment of solid tumors with cycloplatam alone in urinary bladder tumors, cervical carcinoma and malignant pleurites of various etiology as well as in combination with other cytostatics (carcinoma of the prostate, pleural mesothelioma and urinary bladder tumors).
  • The drug may be recommended both for oral and intracavitary administration; side-effects may include moderate toxicity, chiefly, hematological one.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Deoxycytidine / analogs & derivatives. Mesothelioma / drug therapy. Organoplatinum Compounds / therapeutic use. Pleural Neoplasms / drug therapy. Prostatic Neoplasms / drug therapy. Urinary Bladder Neoplasms / drug therapy. Uterine Cervical Neoplasms / drug therapy. Vinblastine / analogs & derivatives
  • [MeSH-minor] Adult. Aged. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Agents, Phytogenic / administration & dosage. Female. Humans. Male. Middle Aged. Pleurisy / etiology. Prostate-Specific Antigen / blood. Time Factors

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. VINORELBINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11826504.001).
  • [ISSN] 0507-3758
  • [Journal-full-title] Voprosy onkologii
  • [ISO-abbreviation] Vopr Onkol
  • [Language] rus
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Comparative Study; English Abstract; Journal Article; Multicenter Study
  • [Publication-country] Russia
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Phytogenic; 0 / Organoplatinum Compounds; 0W860991D6 / Deoxycytidine; 109837-67-4 / cycloplatam; 5V9KLZ54CY / Vinblastine; B76N6SBZ8R / gemcitabine; EC 3.4.21.77 / Prostate-Specific Antigen; Q6C979R91Y / vinorelbine
  •  go-up   go-down


22. Misset JL, Bleiberg H, Sutherland W, Bekradda M, Cvitkovic E: Oxaliplatin clinical activity: a review. Crit Rev Oncol Hematol; 2000 Aug;35(2):75-93
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Oxaliplatin (Eloxatin), a recently developed third-generation cisplatin analogue with a 1,2-diaminocyclohexane (DACH) carrier ligand, has displayed preclinical and clinical activity in a wide variety of tumour types.
  • Trials in pretreated and untreated advanced ovarian cancer (AOC), as a single agent or in combination with cisplatin, cyclophosphamide or paclitaxel, indicate a yet to be defined role in AOC and confirm its lack of cross-resistance with cis/carboplatin.
  • Clinical investigations of single agent and combination therapies in breast, lung, prostate and germ-cell carcinomas, non-Hodgkin's lymphoma and malignant mesothelioma are being pursued.
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Clinical Trials as Topic. Colorectal Neoplasms / drug therapy. DNA Adducts / therapeutic use. Drug Resistance. Female. Humans. Ovarian Neoplasms / drug therapy. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10936465.001).
  • [ISSN] 1040-8428
  • [Journal-full-title] Critical reviews in oncology/hematology
  • [ISO-abbreviation] Crit. Rev. Oncol. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] IRELAND
  • [Chemical-registry-number] 0 / DNA Adducts; 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin
  • [Number-of-references] 113
  •  go-up   go-down


23. Kim MP, Hofstetter WL: Tumors of the diaphragm. Thorac Surg Clin; 2009 Nov;19(4):521-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The most common primary malignant lesion is rhabdomyosarcoma.
  • Malignant tumors are treated based on histology and often with chemotherapy and/or radiation along with surgical resection if feasible.
  • Endometriosis, a benign process that metastasizes to the diaphragm, is typically treated medically; surgical ablation or resection is considered only after failed conservative treatment.
  • Surgical resection of metastatic malignant tumors, such as ovarian cancer and thymoma, as well as malignancies affecting the diaphragm by direct extension, such as mesothelioma, lung, and esophageal cancer, may provide some survival advantage.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20112635.001).
  • [ISSN] 1547-4127
  • [Journal-full-title] Thoracic surgery clinics
  • [ISO-abbreviation] Thorac Surg Clin
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 70
  •  go-up   go-down


24. Davidson B: Biological characteristics of cancers involving the serosal cavities. Crit Rev Oncog; 2007 Dec;13(3):189-227
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumor cells in effusions most frequently originate from primary carcinomas of the ovary, breast, and lung, and from malignant mesothelioma, a native tumor of this anatomic site.
  • Unlike the majority of solid tumors, particularly at the primary site, cancer cells in effusions are not amenable to surgical removal and failure in their eradication is one of the main causes of treatment failure.
  • In recent years, we have studied the biological characteristics of ovarian carcinoma, breast carcinoma, and malignant mesothelioma cells in effusions and compared it to their counterparts in primary tumors and solid metastases.
  • In ovarian carcinoma, several of these molecules are differentially expressed in primary diagnosis (prechemotherapy) and disease recurrence (postchemotherapy) specimens, reflecting the effect of disease progression and chemotherapy, and have different prognostic significance as function of disease progression.
  • The findings presented in this review underscore the need to take into consideration the unique biology of cancer cells in effusions if patient-tailored molecular therapy is to become a successful treatment modality in these malignancies.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18298385.001).
  • [ISSN] 0893-9675
  • [Journal-full-title] Critical reviews in oncogenesis
  • [ISO-abbreviation] Crit Rev Oncog
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Caenorhabditis elegans Proteins; 0 / Cell Adhesion Molecules; 0 / Cytokines; 0 / EFN-4 protein, C elegans; 0 / Ephrins; 0 / Intercellular Signaling Peptides and Proteins; 0 / Receptors, Growth Factor
  • [Number-of-references] 167
  •  go-up   go-down


25. Pearce HL, Alice Miller M: The evolution of cancer research and drug discovery at Lilly Research Laboratories. Adv Enzyme Regul; 2005;45:229-55
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The evolution of cancer research and drug discovery at Lilly Research Laboratories.
  • This review highlights the discovery and development of chemotherapy at Eli Lilly & Company over the past 30 years from the Vinca alkaloids-vincristine, vinblastine, and vindesine-to targeted therapy.
  • Two such agents, gemcitabine and pemetrexed, underwent clinical development and are now among Lilly's portfolio of approved anticancer drugs.
  • Gemcitabine, a pyrimidine nucleoside that has a profound effect on DNA synthesis, has been approved for the treatment of pancreatic, non-small cell lung, bladder, and most recently, breast, and ovarian cancer.
  • Pemetrexed, given in combination with cisplatin, has been recently approved for the treatment of malignant pleural mesothelioma and as second-line treatment for non-small cell lung cancer.
  • Spurred by advances in the understanding of cancer as a disease process, Lilly's anticancer drug program began to transition to a more "targeted" approach during the 1990s.
  • [MeSH-major] Antineoplastic Agents / history. Drug Industry / history. Neoplasms / history
  • [MeSH-minor] Clinical Trials as Topic. Deoxycytidine / analogs & derivatives. Deoxycytidine / history. Deoxycytidine / pharmacology. Deoxycytidine / therapeutic use. Glutamates / history. Glutamates / pharmacology. Glutamates / therapeutic use. Guanine / analogs & derivatives. Guanine / history. Guanine / pharmacology. Guanine / therapeutic use. History, 20th Century. Humans. Indoles / history. Indoles / pharmacology. Indoles / therapeutic use. Pemetrexed. United States

  • Hazardous Substances Data Bank. PEMETREXED .
  • Hazardous Substances Data Bank. GUANINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16143373.001).
  • [ISSN] 0065-2571
  • [Journal-full-title] Advances in enzyme regulation
  • [ISO-abbreviation] Adv. Enzyme Regul.
  • [Language] eng
  • [Publication-type] Historical Article; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Glutamates; 0 / Indoles; 04Q9AIZ7NO / Pemetrexed; 0W860991D6 / Deoxycytidine; 5Z93L87A1R / Guanine; B76N6SBZ8R / gemcitabine; UC96G28EQF / enzastaurin
  •  go-up   go-down


26. Grande C, Firvida JL, Navas V, Casal J: Interleukin-2 for the treatment of solid tumors other than melanoma and renal cell carcinoma. Anticancer Drugs; 2006 Jan;17(1):1-12
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interleukin-2 for the treatment of solid tumors other than melanoma and renal cell carcinoma.
  • It has been used to stimulate the immune system for the treatment of multiples tumors.
  • This article is intended to review the reports published from 1990 to 2004 on the IL-2 treatment of tumors other than melanoma and renal carcinoma.
  • A selection was made over 150 publications reporting on administration of IL-2 in multiple tumors: lung carcinoma (small cell and non-small cell), colorectal, gastric, pancreatic, ovarian and breast cancer, sarcomas, hepatocarcinoma, mesothelioma, and brain, urological, and head and neck tumors.
  • IL-2 was mainly used in metastatic disease, associated with other immunotherapy or chemotherapy schedules.
  • We conclude that adjuvant IL-2 may be of value in early stages combined with standard treatment for colon and pancreas cancers.
  • Assessment of the efficacy of IL-2 combined with chemotherapy as treatment for advanced stages is complex, due to the lack of a control, and the variety of dosages and schemes.
  • The activity of IL-2 in monotherapy or in association with immunotherapy is clinically relevant in hepatocarcinoma, mesothelioma and in malignant overflows as palliative treatment.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Interleukin-2 / therapeutic use. Neoplasms / drug therapy
  • [MeSH-minor] Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Small Cell / drug therapy. Clinical Trials as Topic. Colorectal Neoplasms / drug therapy. Humans. Lung Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16317284.001).
  • [ISSN] 0959-4973
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interleukin-2
  • [Number-of-references] 154
  •  go-up   go-down


27. Santhanam S, Decatris M, O'Byrne K: Potential of interferon-alpha in solid tumours: part 2. BioDrugs; 2002;16(5):349-72
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The second part of this review examines the use of recombinant interferon-alpha (rIFNalpha) in the following solid tumours: superficial bladder cancer, Kaposi's sarcoma, head and neck cancer, gastrointestinal cancers, lung cancer, mesothelioma and ovarian, breast and cervical malignancies.
  • In superficial bladder cancer, intravesical rIFNalpha has a promising role as second-line therapy in patients resistant or intolerant to intravesical bacille Calmette-Guérin (BCG).
  • In neuroendocrine tumours, including carcinoid tumour, low-dosage (</=3 MU) or intermediate-dosage (5 to 10 MU) rIFNalpha is indicated as second-line treatment, either with octreotide or alone in patients resistant to somatostatin analogues.
  • Intracavitary IFNalpha may be useful in malignant pleural effusions from mesothelioma.
  • Similarly, intraperitoneal IFNalpha may have a role in the treatment of minimal residual disease in ovarian cancer.
  • IFNalpha may have a role as a radiosensitising agent for the treatment of cervical cancer; however, this requires confirmation in randomised trials.
  • On the basis of current evidence, the routine use of rIFNalpha is not recommended in the therapy of head and neck squamous cell cancers, upper gastrointestinal tract, colorectal and lung cancers, or mesothelioma.
  • Further data from randomised studies in solid tumours are needed where rIFNalpha has activity, such as neuroendocrine tumours, minimal residual disease in ovarian cancer, and cervical cancer.
  • Studies of IFNalpha-stimulated gene expression, which are now feasible, should help to identify molecular predictors of response and allow us to target therapy more selectively to patients with solid tumours responsive to IFNalpha.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Interferon-alpha / therapeutic use. Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12408739.001).
  • [ISSN] 1173-8804
  • [Journal-full-title] BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
  • [ISO-abbreviation] BioDrugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha
  • [Number-of-references] 391
  •  go-up   go-down


28. Vaporciyan AA, Putnam JB Jr, Smythe WR: The potential role of aprotinin in the perioperative management of malignant tumors. J Am Coll Surg; 2004 Feb;198(2):266-78
Hazardous Substances Data Bank. APROTININ .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The potential role of aprotinin in the perioperative management of malignant tumors.
  • [MeSH-major] Aprotinin / therapeutic use. Neoplasms / drug therapy. Serine Proteinase Inhibitors / therapeutic use
  • [MeSH-minor] Animals. Blood Loss, Surgical / prevention & control. Disease Progression. Female. Hemostasis. Humans. Kallikreins / physiology. Kidney / drug effects. Meningeal Neoplasms / surgery. Meningioma / surgery. Mesothelioma / surgery. Neoplasm Invasiveness. Neoplasm Metastasis / prevention & control. Neovascularization, Pathologic / physiopathology. Ovarian Neoplasms / physiopathology. Pneumonectomy. Sarcoma / surgery. Urinary Bladder Neoplasms / surgery. Urokinase-Type Plasminogen Activator / antagonists & inhibitors

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14759785.001).
  • [ISSN] 1072-7515
  • [Journal-full-title] Journal of the American College of Surgeons
  • [ISO-abbreviation] J. Am. Coll. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Serine Proteinase Inhibitors; 9087-70-1 / Aprotinin; EC 3.4.21.- / Kallikreins; EC 3.4.21.73 / Urokinase-Type Plasminogen Activator
  • [Number-of-references] 75
  •  go-up   go-down






Advertisement